857334-79-3

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-(4-benzylpiperazin-2-yl)ethanol-2HCl is used as a potential candidate for drug development due to its structural properties. It may be utilized in the creation of medications targeting neurological disorders, capitalizing on its interaction with specific receptors or pathways within the nervous system.
Additionally, it is considered as a potential psychoactive substance for further research, given its chemical structure and classification within the phenylpiperazine family. This could lead to applications in the treatment of mental health conditions or as a component in the development of novel therapeutic agents.
However, it is important to note that further research is required to fully understand the properties, efficacy, and safety of (R)-2-(4-benzylpiperazin-2-yl)ethanol-2HCl before it can be integrated into pharmaceutical applications.

Upstream product

• 1485770-18-0 (R)-dimethyl 2-(2-chloroacetamido)succinate 
• 857334-77-1 (R)-benzyl 2-(4-benzyl-3,6-dioxopiperazin-2-yl)acetate 
• 6436-90-4 ethyl 2-(benzylamino)acetate 

Downstream Products

• 660862-46-4 (R)-2-(piperazin-2-yl)ethan-1-ol 

Relevant academic research and scientific papers

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.

Asymmetric syntheses of (R)-4-halo-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines, important 5-HT2C agonist precursors

Asymmetric syntheses of N-protected (R)-4-halo-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines, advanced intermediates for the synthesis of highly potent and selective 5-HT2C agonists, are described. The key transformation involves ring opening of N-protected bicyclic sulfamidate (R)-hexahydro-3H-pyrazino[1,2-c][1,2,3]oxathiazine 1,1-dioxide with (4-halo-2-fluoropyridin-3-yl)lithiums or (3-bromo-5-fluoropyridin-4-yl)lithium. In situ hydrolyses of the resultant sulfamic acids and subsequent intramolecular nucleophilic aromatic substitutions (SNAr) produce the enantiopure tricycles. The two step procedure represents new methodology for the stereoselective syntheses of tetrahydronaphthyridines.

HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS

The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, espec

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for usi